Dedicated to developing treatments for neurodegenerative diseases
Alpha Cognition is a clinical-stage, biopharmaceutical company. Their main focus is to develop treatments for neurodegenerative diseases, like Alzheimer’s, Dementia, and Amyotrophic Lateral Sclerosis (ALS).
ALPHA-1062 is a patented new chemical entity that has demonstrated safety and improved tolerability in human clinical trials. Furthermore, it is a prodrug of an approved AChEl, galantamine.
CEO, Michael McFadden says, “It will be one of the first innovations, if approved, in Alzheimer’s in over a decade.”
Additionally, ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. Moreover, it is in preclinical development for the treatment of ALS. Not to mention, ALPHA-0602 is patented and has received Orphan Drug Designation from the FDA.
For more information on Alpha Cognition (TSX.V: ACOG, OTCQB: ACOGF) please click the investor request info button.